Previsão

Não temos dados de analistas para esta empresa.

Notícias Ir para o feed de notícias

Cogent Communications bets on wavelength growth and Sprint integration by mid-2028

At the Oppenheimer conference, Cogent Communications outlined targets of $1.5 billion in revenue and $500 million in EBITDA by mid-2028, driven by the Sprint acquisition and expansion of its wavelength business. The company plans a market entry in India, is reviewing the sale of non-core assets, and expects sequential revenue growth from Q1 2025 despite short-term declines from Sprint and reduced T‑Mobile subsidies. » Mais em de.investing.com
Crown Castle starts strategic realignment after $8.5 billion sale

Crown Castle will sell its fiber and small-cell business for $8.5 billion and reposition itself as a pure US tower operator, with $6 billion earmarked to pay down debt and the remainder for share buybacks. The company raised its outlook for tower leasing, is targeting an investment-grade rating, and named Christian Hildenbrand as its new CEO starting in September. Regulatory approvals, including a second request from the US-Justizministerium, are progressing as planned; Sprint churn and minimal effects from the T-Mobile/U.S. Cellular transactions were also noted. » Mais em de.investing.com

Dados financeiros da empresa

No último trimestre, SPRINT BIOSCIENCE AB registou receitas de € 0 e um ganho líquido de -€ 1,46 mi

(EUR)	junho de 2026	YoY
Receitas	0	100,00%
Ganho bruto	-25,27 mil	103,21%
Ganho líquido	-1,46 mi	121,02%
EBITDA	-1,47 mi	155,18%

Dados fundamentais

Métrica	Valor
Capitalização bolsista	€ 27,59 mi
Número de ações	105,52 mi
Máximo/mínimo de 52 semanas	€ 0,41 - € 0,047
Dividendos	Não
Beta	-0,52
PER (PE Ratio)	4,10
PEG (PEG Ratio)	0,01
P/VC (PB Ratio)	3,46
P/V (PS Ratio)	2,24

Perfil da empresa

Sprint Bioscience AB (publ) entwickelt pharmazeutische Produkte in den Bereichen Krebs und Stoffwechsel in Schweden, Europa, den Vereinigten Staaten und Asien. Das Unternehmen entwickelt VPS34, einen Arzneimittelkandidaten für die Behandlung verschiedener Krebsarten, und PETRA01, einen Arzneimittelkandidaten für die Behandlung von Krebs. Das Unternehmen konzentriert sich auch auf die Erforschung von Produkten für die Behandlung des Tumorstoffwechsels und von Typ-2-Diabetes. Sprint Bioscience AB (publ) wurde 2009 gegründet und hat seinen Sitz in Huddinge, Schweden.